Brief: Alligator Bioscience, Aptevo Therapeutics Announce Positive Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study

Alligator Bioscience AB

07/03/2024 15:34

March 7 (Reuters) - 
    Alligator Bioscience and Aptevo Therapeutics:
  
    * ALLIGATOR BIOSCIENCE: POSITIVE INTERIM DATA OF DOSE
ESCALATION
PHASE OF ALG.APV-527 PHASE 1 STUDY IN SOLID TUMOR CANCERS
EXPRESSING TUMOR ANTIGEN 5T4
    * ALLIGATOR BIOSCIENCE AB: INITIAL INTERIM DATA SHOW
FAVORABLE
DRUG EXPOSURE AND CONFIRM ALG.APV-527 BIOLOGICAL ACTIVITY

Further company coverage:  APVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))